Previous Article | Next Article 
Molecular and Cellular Biology, October 1999, p. 7020-7030, Vol. 19, No. 10
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Substrate Targeting of the Yeast Cyclin-Dependent
Kinase Pho85p by the Cyclin Pcl10p
Wayne A.
Wilson,
Alan M.
Mahrenholz, and
Peter J.
Roach*
Department of Biochemistry and Molecular
Biology, Indiana University School of Medicine, Indianapolis,
Indiana 46202
Received 29 April 1999/Returned for modification 18 June
1999/Accepted 26 July 1999
 |
ABSTRACT |
In Saccharomyces cerevisiae, PHO85 encodes
a cyclin-dependent protein kinase (Cdk) catalytic subunit with multiple
regulatory roles thought to be specified by association with different
cyclin partners (Pcls). Pcl10p is one of four Pcls with little sequence similarity to cyclins involved in cell cycle control. It has been implicated in specifying the phosphorylation of glycogen synthase (Gsy2p). We report that recombinant Pho85p and Pcl10p produced in
Escherichia coli reconstitute an active Gsy2p kinase in
vitro. Gsy2p phosphorylation required Pcl10p, occurred at
physiologically relevant sites, and resulted in inactivation of Gsy2p.
The activity of the reconstituted enzyme was even greater than
Pho85p-Pcl10p isolated from yeast, and we conclude that, unlike many
Cdks, Pho85p does not require phosphorylation for activity. Pcl10p
formed complexes with Gsy2p, as judged by (i) gel filtration of
recombinant Pcl10p and Gsy2p, (ii) coimmunoprecipitation from yeast
cell lysates, and (iii) enzyme kinetic behavior consistent with Pcl10p
binding the substrate. Synthetic peptides modeled on the sequences of known Pho85p sites were poor substrates with high
Km values, and we propose that Pcl10p-Gsy2p
interaction is important for substrate selection. Gel filtration of
yeast cell lysates demonstrated that most Pho85p was present as a
monomer, although a portion coeluted in high-molecular-weight fractions
with Pcl10p and Gsy2p. Overexpression of Pcl10p sequestered most of the
Pho85p into association with Pcl10p. We suggest a model for Pho85p
function in the cell whereby cyclins like Pcl10p recruit Pho85p from a
pool of monomers, both activating the kinase and targeting it to substrate.
 |
INTRODUCTION |
The budding yeast,
Saccharomyces cerevisiae, contains a small family of some
five cyclin-dependent protein kinases (Cdks) (27). Though
studied mainly from the perspective of cell cycle progression, yeast
Cdks are also involved in other cellular processes, including the
regulation of transcription (for reviews, see references 10,
46, and 55) and the direct control of
metabolic enzymes (23, 24, 70). However, most knowledge
about Cdk regulation and function comes from study of classic cell
cycle Cdks, Cdc28p in yeast and its mammalian counterparts Cdc2, Cdk2,
Cdk4, and Cdk6 (reviewed in reference 43). These
Cdks are activated by high-affinity association with cyclins, which
were first identified and named as proteins whose levels oscillated
during the cell cycle (26). Since the levels of some cyclins
are now known to be invariant, the definition must be revised to
include structurally related proteins that bind to and activate Cdks
(44). However, this commonality of function does not
correspond to a particularly high degree of sequence similarity. All
cyclins share a cyclin box (26) which forms a set of five
-helices involved in the interaction with the Cdk (2,
28). The three-dimensional structures of cyclin A and cyclin H
revealed a COOH-terminal structural repeat of this fold that was not
predicted from inspection of the sequence. In addition to cyclin
binding, activation of Cdks requires phosphorylation of a specific
threonine residue located in the activation loop of the Cdk by a
distinct upstream Cdk-activating kinase (Cak) (reviewed in reference
44). For example, yeast Cdc28p is phosphorylated on
Thr169 in a reaction likely catalyzed by Cak1p (15, 31, 69).
This mechanism is conserved in mammalian Cdks (45, 46).
Most Cdks interact with multiple cyclin subunits (1, 43).
Structural studies suggest that only one cyclin can associate with a
Cdk molecule at any given time and so formation of different Cdk-cyclin
complexes is thought to allow the catalytic subunit to carry out
different functions, presumably by dictating the substrate specificity
of the kinase complex. However, direct biochemical evidence has proved
difficult to obtain, in part because so few genuine Cdk substrates are
known. Recently, we showed that the substrate specificity of one of the
yeast Cdks, Pho85p, is indeed determined by association with particular
cyclins (24). PHO85 was first identified by
virtue of its involvement in the transcriptional repression of
nonspecific acid phosphatases, such as Pho5p (37, 71, 73).
In this instance, Pho85p acts together with the cyclin Pho80p to
phosphorylate and prevent the nuclear localization of a transcription
factor, Pho4p, required for PHO5 expression (29, 47). Pho85p is now thought to be involved in a variety of
cellular processes (16, 41, 67) and can interact with 10 different cyclin partners, or Pcls (Pho80p, Pcl1p and Pcl2p, Clg1p, and Pcl5p through Pcl10p) (42). Four of these cyclins, Pcl6p,
Pcl7p, Pcl8p, and Pcl10p, have the cyclin box located close to the COOH terminus and thus lack the second repeat of the five-helix fold found
in the classic cyclins.
We found that Pcl8p and Pcl10p were involved in glycogen metabolism
and, more specifically, that Pho85p-Pcl10p directly phosphorylated the
predominant form of yeast glycogen synthase, Gsy2p (24), whose phosphorylation regulates glycogen storage (20, 21, 58). In the same study, we showed that association of Pho85p with
Pcl10p generated a specific Gsy2p kinase that only poorly phosphorylated Pho4p in vitro. Conversely, Pho85p-Pho80p formed a
selective Pho4p kinase that had low activity towards Gsy2p. This cyclin
specificity in vitro was mirrored in vivo: disruption of
PCL8 and PCL10 affected only glycogen
accumulation, whereas deletion of PHO80 was specific for
acid phosphatase expression.
The Pho85p system provides a good example of individual cyclins
determining the specificity of the Cdk towards known, physiological substrates of the kinase. In the present investigation, we have extended this work to study the role of the cyclin Pcl10p in
determining substrate selection by Pho85p. Pcl10p is absolutely
required for phosphorylation of the substrate Gsy2p by Pho85p. However,
Pcl10p alone can also form complexes with Gsy2p, and we propose that this interaction contributes to the process of substrate recognition and effective phosphorylation. Since most Pho85p in cell extracts is
monomeric, it is likely that Pcls are limiting and serve to recruit
Pho85p from a cellular pool as needed for targeted protein phosphorylation.
 |
MATERIALS AND METHODS |
Strains and media.
Standard bacterial and yeast culture
conditions and techniques for manipulation were used throughout
(19, 59). The yeast strain WW10 (MAT
ura3-52 leu2 trp1 pcl8::TRP1
pcl10::LEU2) was derived from DH96-52 (MAT
ura3-52 leu2 trp1 pcl8::TRP1) (24) by
disruption of the PCL10 gene with LEU2, using a
PCR strategy (3). A similar PCR strategy was used to
generate strain WW11 (MAT
ura3-52 leu2 trp1
pho85::TRP1) from EG328-1A (MAT
ura3-52 leu2 trp1). Strain CC9 (MAT
ura3-52 leu2 trp1 glg1-2::LEU2
glg2::URA3) is described elsewhere (7). The
strains DH96-52 and CC9 are derived from EG328-1A. Strain BY391a
(MATa trp1
63 GAL2+ ura3-52
lys2-801am ade2-107o his3
200
leu2-
1) is described elsewhere (41).
Plasmids.
Plasmids were constructed and maintained in
Escherichia coli DH5
. All DNA segments generated by PCR
were sequenced prior to use. The plasmid pET-HisPHO85 was constructed
as follows. PCR was employed to amplify the PHO85 open
reading frame from a genomic clone of PHO85 kindly provided
by Brenda Andrews, University of Toronto, Toronto, Ontario, Canada. The
primers used introduced an NdeI site at the initiation codon
immediately followed by a tag of six histidine residues and a
BamHI site 3 bp beyond the stop codon. For expression in
E. coli, this DNA fragment was digested with NdeI
and BamHI and ligated into pET-3c (Novagen).
Plasmid pET-HAPCL10 was constructed by first amplifying the
PCL10 open reading frame from a bacteriophage
MG3 clone
of yeast chromosomal DNA (49) obtained from the American
Type Tissue Collection (ATCC 70674). Amplification was conducted in two
stages. First, a portion of PCL10 from the 5' end to an
internal HindIII site was produced. The sense primer
used introduced an NdeI site followed by a copy of the
hemagglutinin (HA) epitope (MYPYDVPDYA). The remainder of the
PCL10 open reading frame, from the internal HindIII site to the 3' end, was then amplified. The
antisense primer used introduced a BamHI site 3 bp beyond
the stop codon. The 5' and 3' ends of PCL10 were joined by
using the HindIII site, and the resulting full-length
sequence was ligated into pET-3c as an NdeI/BamHI
fragment, generating pET-HAPCL10. To allow for coexpression studies in
E. coli, a ClaI/SphI piece containing the T7 promoter and the HAPCL10 coding region was excised
from pET-HAPCL10 and used to replace a ClaI/SphI
segment of pACYC184 (5), which carries the origin of
replication from plasmid p15A, creating pACYC-HAPCL10.
An alternative
PCL10 construct was also created. A portion
of
PCL10 from the 5' end to the internal
HindIII site was again
amplified, but in this case, the
sense primer introduced an
NdeI
site followed by a tag of
six consecutive histidine residues.
This segment of
PCL10
was joined to the 3' end generated above
with the
HindIII site. The full-length
PCL10 thus
created was
ligated into pET-3c as an
NdeI/
BamHI
fragment, generating pET-HisPCL10.
Plasmids pMET-PHO85 and pMET-PHO85 S166A/S167A were used to express
either wild-type Pho85p or Pho85p in which two adjacent
serine residues
in the activation loop had been changed to alanine
in yeast strain
BY391a. These vectors were gifts from Dongqing
Huang and Brenda
Andrews, University of Toronto, and contain the
promoter from
MET3 and the
PHO85 open reading frame in a
backbone
derived from pRS313 (
65).
Synthetic peptides.
Synthetic peptides were synthesized by
Macromolecular Resources, Colorado State University. Three peptides
were made, based upon the sequences surrounding the sites
phosphorylated by Pho85p in Gsy2p (23, 24) and Pho4p
(47). The peptide sequences used were as follows: Gsy2-654,
KKLSVPGSPRDLRS; Gsy2-667,
KKSTVYMTPGDLGT; and Pho4-114,
KKPRLLYSPLIHTQ, with the phosphorylated residue underlined in each case.
Protein expression and purification.
HisPho85p and HisPcl10p
were isolated after transformation of E. coli BL21(DE3) with
the appropriate pET plasmids described above. Cells were grown at
37°C in Luria-Bertani (LB) medium supplemented with ampicillin (100 µg/ml) until an optical density at 600 nm of 0.6 was reached. Protein
expression was induced by the addition of
isopropyl-
-D-thiogalactopyranoside (IPTG) to 0.4 mM, and
the cultures were transferred to 30°C. After 4 h, cells were
collected by centrifugation (5,000 × g, 10 min,
4°C), washed, and then resuspended with homogenization buffer (20 mM
Tris-HCl [pH 7.9], 500 mM NaCl, 10 mM imidazole, 0.1% [vol/vol]
Triton X-100, 0.5 µg of leupeptin per ml, 0.7 µg of pepstatin per
ml, 1 µg of aprotinin per ml, 10 µg of trypsin inhibitor per ml, 2 mM benzamidine, 0.1 mM
N
-p-tosyl-L-lysine chloromethyl
ketone [TLCK], 1 mM phenylmethylsulfonyl fluoride [PMSF]). All
subsequent steps were performed at 4°C. Cells were broken by two
passes through a French pressure cell, and cell debris was removed by
centrifugation (20,000 × g, 15 min). The supernatant was mixed with 1.5 ml of Ni2+-NTA-agarose
(Qiagen), equilibrated in homogenization buffer for 1 h, and then
packed into a 5-ml chromatography column. The column was washed with 15 ml of homogenization buffer, followed by 15 ml of buffer with the
imidazole concentration raised to 50 mM. Bound protein was eluted by
washing the column with 7.5 ml of homogenization buffer containing 200 mM imidazole. The eluted material was dialyzed against a storage buffer
containing 50 mM Tris-HCl (pH 7.5), 1 mM dithiothreitol (DTT), 1 mM
benzamidine, and 0.1 mM PMSF and then concentrated with Amicon
Centricon-10 (Pho85p) or Centricon-30 (Pcl10p) centrifugal
concentration devices. Glycerol was added to 20% (vol/vol), and the
material was stored frozen at
80°C where it was stable for at least
4 months, through multiple cycles of freezing and thawing. Typical
yields were 1 to 3 mg of purified protein per liter of bacterial culture.
For coexpression studies,
E. coli BL21(DE3) was
simultaneously transformed with vectors pET-HisPHO85 and pACYC-HAPCL10.
Transformants
were cultured in LB medium (
59) supplemented
with both ampicillin
(100 µg/ml) and chloramphenicol (40 µg/ml).
Expression of recombinant
proteins was induced as described above.
After induction, samples
of culture (2 ml) were collected by
centrifugation (10,000 ×
g,
30 s, 4°C). Cell pellets
were resuspended to 200 µl with homogenization
buffer, frozen on dry
ice, and stored at

80°C prior to use. Cell
lysates were prepared by
sonication (four 15-s pulses with 2 min
of cooling on ice between each
pulse) and used directly for phosphorylation
of
Gsy2p.
To produce Pcl10p in yeast, strain WW10 was transformed with pYES2/GS
(Invitrogen) containing the
PCL10 open reading frame.
Pcl10p
production was induced by first growing cultures in supplemented
minimal medium lacking uracil (0.67% [wt/vol] yeast nitrogen base
without amino acids [Difco] containing complete supplement mixture
without uracil [Bio 101 Inc.]) and with 1% raffinose as a carbon
source. Cells were then transferred to a medium containing 1%
raffinose plus 2% galactose and allowed to grow for 24 h. The
six-histidine tag encoded by the pYES2/GS vector was used to facilitate
isolation of Pcl10p. Cells were collected by centrifugation
(5,000
×
g, 10 min, 4°C), washed and resuspended at
1 g (wet weight)
of cells/ml in a homogenization buffer comprising
20 mM Tris-HCl
(pH 7.9), 450 mM NaCl, 50 mM NaF, 5 mM imidazole, 0.1%
(vol/vol)
Triton X-100, and protease inhibitors as described above. All
subsequent steps were performed at 4°C. Cells were broken by vigorous
mixing in the presence of glass beads (0.4-mm diameter). Cell
debris
was removed by centrifugation (20,000 ×
g, 30 min).
The
supernatant was mixed with 0.5 ml of Ni
2+-NTA-agarose
for 1 h, and the resin was packed into a 2-ml chromatography
column. The column was washed first with 5 ml of homogenization
buffer
and then sequentially with 5 ml (each) of homogenization
buffer with
the imidazole concentration raised to 20 mM and 40
mM. The material
eluted with 40 mM imidazole was dialyzed against
a solution containing
50 mM Tris-HCl (pH 7.5), 1 mM DTT, 1 mM
benzamidine, and 0.1 mM PMSF
and then concentrated as described
above. Gsy2p was expressed in
E. coli BL21(DE3) and purified as
described previously
(
23). Construction of the phosphorylation
site mutants of
Gsy2p is described elsewhere (
24).
Assay of Gsy2p kinase activity. (i) Indirect measurement of
phosphorylation.
Phosphorylation converts Gsy2p to a less active
form that requires the presence of the allosteric activator
glucose-6-phosphate to elicit full activity. Thus, the ratio of
activity without and with glucose-6-phosphate (
/+ glucose-6-P
activity ratio) can be used as an index of the phosphorylation state of
the enzyme. Purified Gsy2p (5 to 10 µg) was combined with either 3 to
5 µg of total cell lysate from E. coli BL21(DE3)
expressing HisPho85p and/or HAPcl10p or purified HisPho85p and
HisPcl10p in a final volume of 80 µl of kinase buffer (50 mM Tris-HCl
[pH 7.4], 1 mM DTT, 0.1% Triton X-100, and protease inhibitors as
described above). The reaction was initiated by addition of 20 µl of
a mixture of 25 mM MgCl2 and 1 mM ATP, and the samples were
incubated at 30°C. At intervals, aliquots (10 µl) were removed and
diluted to 200 µl with a solution containing 50 mM Tris-HCl (pH 7.8),
25 mM KF, and 20 mM EDTA to terminate phosphorylation. Aliquots (30 µl) were then assayed for glycogen synthase activity as described previously (21, 68).
(ii) Direct measurement of phosphorylation.
HisPho85p and
HisPcl10p were combined with Gsy2p and kinase buffer (as described
above) in a final volume of 20 µl. This mixture was preincubated for
10 min at 30°C, and the reaction was initiated by the addition of 5 µl of a mixture comprising 250 µM [
-32P]ATP
(specific activity, 2,000 to 4,000 dpm/pmol) and 6.25 mM MgCl2. Each set of assays containd control reaction
mixtures lacking substrate. The reaction was terminated after 10 to 15 min by withdrawing 15 µl of solution and spotting it onto squares of
31-ET chromatography paper (Whatman) saturated with a mixture of 20%
(wt/vol) trichloroacetic acid, 1 mM ATP, and 5 mM
Na4P2O7. The squares were washed in
a solution containing 10% (wt/vol) trichloroacetic acid, 0.25 mM ATP,
and 5 mM Na4P2O7. After the squares
were washed for 15 min, the solution was decanted and replaced with 5%
(wt/vol) trichloroacetic acid and washing continued for a further 15 min. Two more washes with 5% (wt/vol) trichloroacetic acid were
performed, followed by a brief rinse with acetone. The paper squares
were dried under a heating lamp, and the incorporation of radioactivity
was determined by liquid scintillation counting. When E. coli lysates were used as a source of kinase, 3 to 5 µg of
E. coli lysate was used in place of HisPcl10p and HisPho85p,
the reaction was terminated by addition of 1 ml of ice-cold buffer (50 mM Tris-HCl [pH 7.9], 500 mM NaCl, 50 mM NaF, 50 mM imidazole, 0.1%
[vol/vol] Triton X-100, and protease inhibitors as described above).
The Gsy2p was then reextracted from the incubation mixture and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography as described previously (24).
Phosphorylation of synthetic peptides.
HisPho85p and
HisPcl10p were combined with kinase buffer (as above) and substrate
peptide in a final volume of 20 µl. The reaction was initiated by
addition of 5 µl of a mixture comprising 250 µM
[
-32P]ATP (specific activity, 2,000 to 4,000 dpm/pmol)
and 6.25 mM MgCl2. After 30-min incubation at 30°C, 15 µl of the reaction mixture was spotted onto P-81 paper (Whatman) and
dropped into 1% (vol/vol) phosphoric acid. The paper squares were
washed three times for 10 min each time with 1% (vol/vol) phosphoric
acid, rinsed briefly with acetone, and dried. Incorporated
radioactivity was determined by liquid scintillation counting.
Mass spectrometry and analysis of protein digests.
HisPho85p
was digested in the gel with sequencing grade trypsin (Boehringer
Mannheim) at a 10:1 substrate/protease ratio overnight. Protein digests
were chromatographed by using a fused silica column (inner diameter,
500 µm; length, 20 cm) packed with Vydac (218TP5x) C18
material by previously published methods (11, 12). Gradients were controlled with an Applied Biosystems/PE 178 high-performance liquid chromatography system employing standard 0.05% trifluoroacetic acid-water- CH3CN solvents at 10 µl min
1.
Column effluents were infused directly into the electrospray ion source
of a Finnigan LCQ ion-trap mass spectrometer which was operating under
software control to determine base peaks in full-scan mode (400 to
2,000 m/z), perform high-resolution scans on the base peak
in a second scan event, and fragmentation analysis of the base peak
according to the mass and charge state determined in the second scan
event. Data were analyzed both manually and by Seaquest software
provided by Finnigan.
Gel filtration. (i) Recombinant Gsy2p and Pcl10p.
Gel
filtration was performed with a Superose 6 HR 10/30 column attached to
a fast protein liquid chromatography system (Pharmacia). The column was
equilibrated with buffer (25 mM Tris-HCl [pH 7.5], 200 mM NaCl) at a
flow rate of 0.3 ml min
1. The column was calibrated using
a series of protein molecular weight standards (Sigma and Pharmacia).
Either purified Gsy2p, purified Pcl10p, or a mixture of Gsy2p and
Pcl10p was injected onto the column. Fractions (1 ml for Gsy2p and
Gsy2p-Pcl10p mixture; 0.3 ml for Pcl10p) were collected, and the
elution positions of the various proteins were determined by activity
measurements and examination of silver-stained SDS-polyacrylamide gels.
(ii) Yeast cell lysates.
Saturated cultures were grown in 10 ml of YPD medium (19) (EG328-1A and CC9) or in 20 ml of
synthetic medium (19) with 1% (wt/vol) raffinose and 2%
(wt/vol) galactose (WW10 transformed with pYES2/GS containing the
PCL10 open reading frame). The extracts were clarified by
centrifugation (17,000 × g, 15 min, 4°C), and the
protein content in the supernatant was determined. Approximately 2 mg
of protein was applied to a Superose 6 column under the conditions described above, except that the buffer contained 1 mM DTT and the
protease inhibitors benzamidine (2 mM), PMSF (0.1 mM), and TLCK (0.1 mM). Fractions (0.3 ml) were collected, and 15-µl aliquots were
analyzed by SDS-PAGE and immunoblotting.
Immunoblotting.
Pho85p was detected by using anti-Pho85p
serum kindly provided by Brenda Andrews, University of Toronto. Yeast
Pcl10p was detected by using an antibody raised against the V5 epitope
(Invitrogen) encoded by the GeneStorm vector sequence, and Gsy2p was
detected by using antiserum raised against a Gsy2p peptide
(21). Enhanced chemiluminescence (Amersham) and horseradish
peroxidase-conjugated secondary antibodies (Sigma) were used for detection.
Immunoprecipitation.
Strain WW10 transformed with pYES2/GS
containing the PCL10 open reading frame was grown and
PCL10 expression was induced as described above. Cell
pellets were collected by centrifugation, washed once, and resuspended
with immunoprecipitation buffer (100 mM NaCl, 0.02% [vol/vol] Triton
X-100, 50 mM Tris-HCl [pH 7.5], plus protease inhibitors as described
above). Cells were broken by using glass beads, and the extract was
clarified by centrifugation (17,000 × g, 15 min,
4°C). The clarified extract was transferred to a fresh tube, and
centrifugation was repeated. Aliquots (200 µl, corresponding to
approximately 3 mg of total protein) of this second supernatant were
used for immunoprecipitation. The cell extract was precleared with
protein A agarose beads (20 µl; Gibco-BRL), and 2.5 µl of anti-V5
antibody (Invitrogen) was added. After incubation for 2 h at 4°C
with rocking, 20 µl of protein A agarose beads were added and the
incubation continued for a further 2 h. The beads were collected
by low-speed centrifugation and washed with 1 ml of immunoprecipitation
buffer. This washing was repeated four more times. The pellets were
resuspended with SDS-PAGE sample buffer, boiled, and analyzed by
SDS-PAGE and immunoblotting with antibody to Gsy2p.
Data analysis.
To analyze enzyme kinetic data that followed
hyperbolic kinetics, the data were fitted to a rectangular hyperbola by
nonlinear regression analysis, using the KaleidaGraph software package
for Macintosh (Synergy Software).
Other methods.
Protein concentrations were measured by the
method of Bradford (4), with bovine serum albumin as a
standard. Glycogen concentrations in cell extracts were determined by
the method of Hardy and Roach (21), and in each case, the
values reported are means of determinations from two separate
transformants measured in duplicate.
 |
RESULTS |
Expression of a functional Pho85p-Pcl10p complex in E. coli.
To produce a functional Gsy2p kinase in E. coli,
we expressed tagged forms of Pho85p and Pcl10p by using the T7 promoter
system. Pho85p had an NH2-terminal six-histidine tag, and
Pcl10p had an NH2-terminal HA epitope tag. These constructs
were coexpressed in the same cells using vectors with different
replication origins (see Materials and Methods). HisPho85p was readily
detected in a crude E. coli lysate after Coomassie blue
staining of an SDS-polyacrylamide gel (see Fig. 2). No Coomassie
blue-stained band corresponding to HAPcl10p was visible, although it
was detected by immunoblotting with antibody to the HA epitope (not
shown). Lysates of E. coli coexpressing Pcl10p and Pho85p
catalyzed the incorporation of 32P from
[
-32P]ATP into Gsy2p, but there was no detectable
incorporation of phosphate with extracts from cells expressing either
Pho85p or Pcl10p alone (Fig. 1A).



View larger version (70K):
[in this window]
[in a new window]
|
FIG. 1.
Expression of a functional Pho85p-Pcl10p complex in
E. coli. (A) Phosphorylation of Gsy2p by lysates of E. coli coexpressing Pho85p and Pcl10p. Cell lysates were prepared
from E. coli carrying either pET-HisPHO85, pACYC-HAPCL10, or
both. Purified, recombinant Gsy2p was incubated with these extracts in
the presence of [ -32P]ATP and MgCl2. The
Gsy2p was then repurified from the incubation mixture with
Ni2+-NTA-agarose and analyzed by SDS-PAGE and
autoradiography. (B) Phosphorylation of mutant Gsy2p. Lysates from
E. coli expressing both Pho85p and Pcl10p were used to
phosphorylate either wild-type (WT) Gsy2p or Gsy2p where combinations
of the known phosphorylation sites (Ser650, Ser654, and Thr667) were
mutated to aspartic acid. The phosphorylated Gsy2p was recovered and
analyzed as described above. (C) Phosphorylation and inactivation of
Gsy2p. Purified recombinant Gsy2p was incubated with lysates prepared
from E. coli coexpressing Pho85p and Pcl10p either in the
presence of MgCl2 and ATP ( ) or MgCl2 alone
( ). At the indicated times, aliquots were removed and the /+
glucose-6-P activity of glycogen was determined.
|
|
Gsy2p is thought to contain three phosphorylation sites, Ser650,
Ser654, and Thr667 (
21), and Pho85p-Pcl10p is responsible
for the phosphorylation of Ser654 and Thr667, both in vivo and
in
vitro, with Thr667 being the preferred site (
23,
24). To
determine whether the recombinant Pho85p-Pcl10p kinase phosphorylated
the relevant sites in Gsy2p, two approaches were used. First,
we
employed a series of mutant Gsy2p species in which two of the
three
phosphorylation sites were mutated to Asp. The mutant substrates
S650D
S654D and S650D T667D were phosphorylated, with S650D S654D
being the
preferred substrate. By comparison, there was no detectable
phosphorylation of the mutant S654D T667D which lacks both
Pho85p-Pcl10p
phosphorylation sites (Fig.
1B). Phosphoamino acid
analysis confirmed
that the S650D S654D mutant contained only
phosphothreonine, while
the S650D T667D mutant contained only
phosphoserine (not shown).
Second, lysates of cells coexpressing Pho85p
and Pcl10p catalyzed
a time-dependent decrease in the

/+ glucose-6-P
activity ratio
(Fig.
1C). This ratio is a kinetic index of the extent
of phosphorylation
of glycogen synthase, with lower values
corresponding with increased
phosphorylation. Therefore, the
Pho85p-Pcl10p kinase phosphorylates
the physiologically important sites
in Gsy2p and inactivates
it.
Although an active glycogen synthase kinase was produced by
coexpression of Pho85p and Pcl10p in
E. coli, we could not
control
the relative levels of expression to produce a defined kinase
complex. Therefore, Pho85p and Pcl10p were expressed and purified
independently. We made a Pcl10p construct with a tag of six histidine
residues at the NH
2 terminus. Both HisPho85p and HisPcl10p
were
soluble, stable, and amenable to purification (Fig.
2), routinely
yielding 1 to 3 mg of
Pho85p or Pcl10p per liter of culture. Densitometric
scanning of
Coomassie blue-stained gels indicated that the Pho85p
was >90% pure,
while the Pcl10p was around 80% pure.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 2.
Purification of Pho85p and Pcl10p expressed in E. coli. Soluble lysates were prepared from E. coli
carrying either pET-HisPHO85 (A) or pET-HisPCL10 (B) as described in
Materials and Methods. A Coomassie blue-stained SDS-polyacrylamide gel
of the soluble fraction of the cell lysate and the soluble material
after purification (~10 µg) using Ni2+-NTA-agarose
chromatography is shown. The positions of molecular size standards (in
kilodaltons) are shown to the left of the gels.
|
|
Reconstitution of active Gsy2p kinase from recombinant Pcl10p and
Pho85p.
Pho85p alone displayed no detectable activity towards
Gsy2p, but addition of Pcl10p generated significant Gsy2p kinase
activity (Fig. 3A). The activity
increased with Pcl10p concentration and saturated at high levels. The
curve was hyperbolic, and the concentration of Pcl10p required for
half-maximal activation was approximately 0.2 µM. When the substrate
concentration was varied at fixed Pcl10p levels, the reaction rate also
reached a saturable, maximum level (Fig. 3B). The curve was not
hyperbolic, and at lower Gsy2p concentrations, there was a linear
dependence of rate on substrate concentration. This linearity is most
clearly seen with the higher Pcl10p concentration in the experiment
shown. When the substrate saturation curves at different Pcl10p levels
are compared, the Vmax achieved was dependent on
the Pcl10p concentration. Thus, with 50 nM Pcl10p, an amount equimolar
with the Pho85p catalytic subunit, the rate soon became independent of
the Gsy2p concentration even though the same amount of Pho85p could
sustain a higher Vmax when Pcl10p was at a
higher level (compare the two curves in Fig. 3B). This type of enzyme
kinetic behavior is exactly what is predicted for a system in which an
obligate activator binds to the substrate prior to the formation of an
active enzyme-substrate complex (64). In this case, Pcl10p
is the activator and Gsy2p is the substrate.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
Characterization of Pho85p-Pcl10p kinase reconstituted
from polypeptides produced in E. coli. (A) Phosphorylation
of Gsy2p by Pho85p requires Pcl10p. Purified Pho85p (80 nM) was
incubated together with Gsy2p (3 µM) and the indicated concentrations
of Pcl10p. After 10 min at 30°C, the phosphorylation reaction was
initiated by the addition of [ -32P]ATP and
MgCl2. After a further 10-min incubation, the reaction was
terminated and the incorporation of 32P into Gsy2p was
determined by liquid scintillation counting. The data were analyzed as
described in Materials and Methods. The concentration of Pcl10p
required to give half the maximal rate was calculated to be ~0.2
µM. (B) Effect of Gsy2p concentration on the rate of phosphorylation.
Pho85p (50 nM) and either 50 nM ( ) or 2 µM ( ) Pcl10p were
incubated with the indicated concentrations of Gsy2p, and the initial
rate of Gsy2p phosphorylation was determined.
|
|
Analysis of recombinant Pho85p by mass spectroscopy.
Many Cdks
require phosphorylation of their activation loop, and for Pho85p,
Santos et al. (60) had reported that phosphorylation of
Ser166 was required for kinase function. Therefore, we attempted to
determine whether the recombinant Pho85p isolated from E. coli contained phosphate at this position. Purified Pho85p was
digested with trypsin, concentrated, and analyzed by electrospray
ionization mass spectrometry. Automated analysis of the fragmentation
data led to the identification of peptides representing ~42% of the Pho85p sequence. Manual examination of data allowed additional identification of peptides comprising 95% of the protein sequence. The
peptide containing Ser166 (AFGIPVNTFSSEVVTLWYR) was clearly observed as
a major species. The calculated m/z for the doubly charged
ion is 1,093.568, and that of the observed ion is 1,093.6. No peptides
corresponding to phosphorylated species (+80 Da) or diphosphorylated
species (+160 Da) were observed. Given the very high levels of material
introduced into the electrospray, we are confident that we should have
detected phosphopeptides present at significant proportions, and we
conclude that recombinant Pho85p does not require phosphorylation of
activation loop residues for kinase activity. This result is consistent
with recent results from Huang and Andrews (22) who have
found that a mutant form of PHO85 in which both Ser166 and
Ser167 are changed to alanine was capable of regulating acid
phosphatase expression. We measured the level of glycogen accumulated
by a pho85 mutant strain (BY391a) transformed with either
empty vector, wild-type PHO85, or the above Ser166Ala
Ser167Ala double mutant. The level of glycogen when empty vector was
present was 5.6 mg of glycogen/mg of protein. When wild-type
PHO85 was expressed, the level was 1.1 mg of glycogen/mg of
protein. When the S166A S167A mutant was expressed, the level was 1.8 mg of glycogen/mg of protein. Thus, if phosphorylation of Ser166 and/or
Ser167 does occur in vivo, such phosphorylation is not required for any
Pho85p function studied so far.
Phosphorylation of peptide substrates by Pcl10p-Pho85p.
Besides by direct interaction with substrate, cyclins like Pcl10p could
also affect Cdk specificity by altering the local sequences preferred
by the kinase active site. In fact, if the known Pho85p sites in Gsy2p
and Pho4p are compared, there is a subtle difference. Four of the five
Pho4p sites have the sequence -S-P-X-I/L- (47), whereas the
two Gsy2p sites have the sequence -V-X-X-S/T-P-X-D-L (23).
Three peptides were synthesized based upon the sequences surrounding
Ser654 and Thr667 in Gsy2p and Ser114 in Pho4p (referred to as
Gsy2-654, Gsy2-667, and Pho4-114, respectively). Phosphorylation of
both Gsy2-654 and Pho4-114 was readily measured, and there was a
hyperbolic dependence of reaction rate on peptide concentration (Fig.
4A). Gsy2-667 was not detectably phosphorylated at the sensitivity of this assay. Although the Vmax values for Pho4-114 and Gsy2-654 were,
respectively, 4 and 25% of that for Gsy2p, the
Km values were much greater (Table 1). In terms of the pseudo-first-order
rate constants (Vmax/Km), the peptides were some 4 orders of magnitude less effective as substrates than was Gsy2p. There was a low but detectable activity towards the synthetic peptides in the absence of added Pcl10p which was
not observed when Gsy2p was the substrate (Fig. 4B). As was true for
Gsy2p, peptide phosphorylation depended on the Pcl10p concentration,
half-maximal activation corresponding to ~0.2 µM Pcl10p, similar to
the value observed with Gsy2p as the substrate. We conclude first that
the process of activation, involving interaction of Pho85p and Pcl10p,
is similar for both peptide substrates and Gsy2p. Second, the peptides
were poor substrates compared to Gsy2p, indicating that local sequence
is not the dominant determinant for recognition. Rather, effective
phosphorylation of the physiological protein substrates may depend more
on targeting interactions between Pcl10p and the substrate, as
discussed below.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 4.
Phosphorylation of synthetic peptide substrates by
Pho85p-Pcl10p. (A) Kinetics of peptide phosphorylation. The indicated
concentrations of synthetic peptides Gsy2-654 ( ), Gsy2-667 ( ),
and Pho4-114 ( ) were incubated with 50 nM Pho85p and 2 µM Pcl10p,
and the initial rate of peptide phosphorylation was determined. Data
were analyzed as described in Materials and Methods. (B)
Phosphorylation of synthetic peptides by Pho85p shows a dependence upon
Pcl10p. Synthetic peptide Gsy2-654 (2.5 mM) was incubated with 50 nM
Pho85p and the indicated concentrations of Pcl10p. The data were
analyzed as described in Materials and Methods. The concentration of
Pcl10p required to give half-maximal peptide phosphorylation was
calculated to be ~0.2 µM.
|
|
Isolation of a Pho85p-Pcl10p complex from yeast.
Although the
Pho85p-Pcl10p proteins expressed in E. coli were able to
reconstitute a functional Gsy2p kinase activity, it was important to
determine precisely how active this material was compared to enzyme
purified from yeast. It was possible, for example, that the activity
detected was low and that in yeast other mechanisms are needed for full
activity. We therefore transformed strain WW10 (pcl8 pcl10)
with a multicopy vector containing the PCL10 open reading
frame. This vector encodes a form of Pcl10p containing a COOH-terminal
tag of six histidine residues and the V5 epitope (Invitrogen), under
the control of the inducible GAL1 promoter. The vector
complemented the glycogen hyperaccumulation defect of the pcl8
pcl10 mutant strain (not shown). Pcl10p was partially purified
from yeast lysates by chromatography on Ni2+-NTA-agarose.
Material eluted from the Ni2+-NTA-agarose column contained
both Pcl10p and Pho85p, as determined by immunoblotting, and was
capable of phosphorylating Gsy2p (Fig. 5A). The peaks of Pho85p, Pcl10p, and
Gsy2p kinase activity were coincident (Fig. 5A). By analyzing known
amounts of recombinant Pho85p in the immunoblotting analysis under the
same conditions, we estimated the absolute amount of Pho85p present in
the peak of kinase activity isolated from yeast (Fig. 5B). In this way, the specific activity of the Pcl10p-Pho85p kinase from yeast could be
compared with that of the kinase reconstituted from proteins expressed
in E. coli (Fig. 5B). The Pho85p produced in E. coli, assayed with a saturating concentration of Pcl10p, was 10- to 15-fold more active than Pho85p-Pcl10p isolated from yeast when the
rate of Gsy2p phosphorylation was normalized to the amount of Pho85p.
However, although the kinase was purified from yeast with a tagged form
of Pcl10p, we cannot formally exclude the possibility that Pcl10p was
limiting. We conclude that the recombinant kinase has activity at least
as high as that purified from yeast.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 5.
Isolation of Pho85p-Pcl10p from yeast. Cell lysates were
prepared from strain WW10 (pcl8 pcl10) expressing
PCL10 from the vector pYES2/GS. Pcl10p was partially
purified from the lysate by chromatography on
Ni2+-NTA-agarose. (A) Column fractions eluting with the
indicated concentrations of imidazole analyzed for the presence of
Gsy2p kinase activity, Pho85p and Pcl10p. (B) Quantification of the
Gsy2p phosphorylation and the degree of phosphorylation achieved with a
defined amount of recombinant Pho85p-Pcl10p under the same
conditions.
|
|
Formation of complexes between Pcl10p and Gsy2p.
The enzyme
kinetic data are consistent with there being interactions between Gsy2p
and Pcl10p. Also, we had previously observed a weak interaction between
Gsy2p and Pho85p in a two-hybrid assay (24). The
availability of purified, recombinant Pcl10p and Gsy2p allowed us to
address this interaction in more detail. Pcl10p, Gsy2p, or a mixture of
the two proteins was analyzed by gel filtration. Pcl10p eluted
predominantly as a peak with an apparent molecular mass of ~110 kDa,
which would be consistent with a dimer of the 48.6-kDa Pcl10p monomer
(Fig. 6). A portion of the Pcl10p eluted earlier in the profile, suggesting the possibility of forming even
larger aggregates. In order to determine whether the oligomeric forms
of Pcl10p were active, fractions from the gel filtration column were
assayed for their ability to activate Pho85p, measured using Gsy2p as a
substrate. The peak of Pho85p-activating activity coincided with the
presence of Pcl10p protein, indicating that all species of Pcl10p
detected were capable of activating Pho85p (Fig. 6). After filtration,
the Pcl10p ran as a doublet on SDS-PAGE. The reason is not known but it
could represent some breakdown of the Pcl10p during the separation.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 6.
Size distribution of recombinant Pcl10p. Pcl10p was
analyzed by gel filtration using a Superose 6 column. Aliquots (15 µl) of each fraction were analyzed by SDS-PAGE and silver staining.
To determine whether the eluted Pcl10p was functional, aliquots were
combined with Pho85p (65 nM), Gsy2p (3 µM), MgCl2, and
[ -32P]ATP. Phosphorylation of Gsy2p was then measured
using the filter paper assay described in Materials and Methods.
|
|
From gel filtration, the estimated molecular mass of Gsy2p was ~75
kDa, close to the calculated subunit molecular mass of
80 kDa (Fig.
7A). When mixtures of Gsy2p and Pcl10p
were analyzed,
the profile of Gsy2p activity was shifted to correspond
to a substantial
increase in size, which we infer to result from
interaction with
Pcl10p. The peak fraction had an estimated molecular
mass on the
order of 500 kDa, and the peak was broader than when Gsy2p
was
analyzed alone (Fig.
7A). Evidently, multiple Gsy2p-Pcl10p
complexes
can be formed. Note, however, that not all Gsy2p was
converted
to the larger size, since there was still Gsy2p activity at
lower
molecular weights. Silver-stained SDS-polyacrylamide gels of the
fractions showed that the presence of Gsy2p protein correlated
with the
activity measurements (Fig.
7B). This result provides
strong evidence
that Pcl10p and Gsy2p interact in solution.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 7.
Interaction between Pcl10p and Gsy2p in vitro and in
vivo. (A) Gsy2p alone ( ) or a mixture of Gsy2p and Pcl10p (in a
1:1.5 molar ratio) ( ) was analyzed by gel filtration using a
Superose 6 column. Fractions were collected, and the glycogen synthase
(GS) activity was measured. (B) Aliquots (15 µl) of each fraction
were analyzed by SDS-PAGE and silver staining. (C) Cell lysates were
prepared from strain WW10 (pcl8 pcl10) and from strain WW11
(pho85) each expressing PCL10 from the vector
pYES2/GS. Immunoprecipitation was carried out as described in Materials
and Methods using antibody to the V5 epitope tag encoded by pYES2/GS (+ anti V5) or an equivalent volume of phosphate-buffered saline ( anti
V5). The immunoprecipitates were analyzed by SDS-PAGE and
immunoblotting with antibody to Gsy2p (Bound). An aliquot (20%) of the
supernatant after addition of protein A agarose beads was also analyzed
(Free).
|
|
To determine whether Gsy2p and Pcl10p might also be associated in vivo,
anti-V5 antibody was used to immunoprecipitate Pcl10p
from extracts of
strains WW10 (
pcl8 pcl10) and WW11 (
pho85)
expressing
the V5-tagged
PCL10 construct described above.
The resulting precipitates
were analyzed by SDS-PAGE and immunoblotting
with antibody raised
against Gsy2p. The anti-V5 antibody coprecipitated
Gsy2p from
the soluble fraction of a yeast cell lysate, suggesting that
Pcl10p
and Gsy2p interact in vivo (Fig.
7C). Similar results were
obtained,
regardless of whether Pho85p was present (WW10) or not
(WW11),
indicating that the interaction between Gsy2p and Pcl10p is
independent
of Pho85p in vivo. The amount of Gsy2p precipitated was
approximately
20% of the total present in the extract. We conclude
that Pcl10p
is able to form complexes with Gsy2p that survive gel
filtration
and immunoprecipitation
protocols.
Size distribution of Gsy2p, Pho85p, and Pcl10p in yeast cell
lysates.
Since the gel filtration and immunoprecipitation studies
indicated interaction between Pcl10p and Gsy2p, the distribution of
Gsy2p, Pcl10p, and Pho85p between the free state and higher-order complexes was examined in extracts of yeast. With lysates of wild-type yeast (strain EG328-1A), two distinct pools of Gsy2p were detected (Fig. 8A), one at very high molecular
mass, ranging into the void volume, and another at 70 to 100 kDa. This
latter pool is around the predicted size of the Gsy2p monomer (80 kDa).
Pho85p was also found in two peaks. One peak corresponded to a size of
~30 kDa, that of free, monomeric Pho85p. The other peak was somewhat
broader, extending in size up to ~170 kDa, and presumably represents
Pho85p associated with Pcls or other proteins.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 8.
Size distribution of Gsy2p, Pho85p, and Pcl10p in yeast
cell lysates. Approximately 2 mg of soluble protein from either
wild-type (WT) yeast (EG328-1A) (A), a glycogen-deficient strain (CC9
[glg1 glg2]) (B), or a strain expressing V5 epitope-tagged
Pcl10p (WW10 [pcl8 pcl10] carrying pYES2/GS containing
PCL10) (C) was analyzed by gel filtration using a Superose 6 column. Fractions (300 µl) were collected from the void volume to the
total volume, and aliquots (15 µl) were analyzed by SDS-PAGE and
immunoblotting.
|
|
Since the Gsy2p running at very high molecular mass might be associated
with glycogen particles, cell extracts were also prepared
from a
glg1 glg2 strain that does not make glycogenin, the
initiator
protein of glycogen biosynthesis. Cells of this strain
contain
the wild-type level of functional glycogen synthase but are
unable
to produce glycogen (
7). Gel filtration of lysates
from
glg1 glg2 double mutants revealed the elimination of
Gsy2p from the
void volume, although some Gsy2p was still detectable in
high-molecular-mass
fractions (Fig.
8B). There was no major change in
the distribution
of Pho85p (Fig.
8B).
In order to investigate the size distribution of Pcl10p, we expressed
the V5 epitope-tagged Pcl10p construct in
pcl10 cells
from a
high-copy-number plasmid, since we currently do not have
anti-Pcl10p
antibodies. After gel filtration, Pcl10p was detected
with anti-V5
antibody. Two clearly defined pools of Pcl10p were
detected, one at
very high molecular mass in the column void volume
and a second
centered around 170 kDa (Fig.
8C). The Pho85p profile
was significantly
changed compared to that of the wild type, with
the majority of the
Pho85p now found at higher molecular weight
and corresponding to the
peak of Pcl10p (Fig.
8C). This result
is consistent with overexpression
of Pcl10p driving the formation
of Pho85p-Pcl10p complexes. We examined
these overexpressing cells
for any abnormalities associated with a lack
of Pho85p function,
reasoning that Pho85p complexed with Pcl10p might
be unavailable
for other functions. However, neither cell morphology
nor the
ability to regulate acid phosphatase expression differed from
that of the wild type (not shown). Therefore, despite being largely
sequestered by Pcl10p, sufficient Pho85p was accessible to fulfill
these other cellular
functions.
 |
DISCUSSION |
We have shown that a functional kinase consisting of the Cdk
catalytic subunit, Pho85p, and the cyclin, Pcl10p, can be reconstituted from recombinant components expressed in E. coli. The kinase
phosphorylates a known in vivo substrate, Gsy2p, at physiologically
relevant sites and to an extent that causes inactivation of Gsy2p. The Pho85p-Pcl10p kinase has several properties that differ from the more
extensively studied cell cycle-regulated Cdks. First, the kinase
catalytic subunit does not appear to require phosphorylation, since the
enzyme formed from recombinant components is at least as active as
Pho85p-Pcl10p kinase prepared from yeast. Also, the recombinant Pho85p
does not appear to contain phosphate at Ser166 due to phosphorylation
during expression in E. coli. Second, Pcl10p activation of
Pho85p requires substantially more than a one-to-one ratio of cyclin to
kinase, with half-maximal activation at ~0.2 µM Pcl10p. If one
infers a binding constant from this value, we are dealing with quite
high affinity, enough to explain the clear evidence for interaction
between Pho85p and Pcl10p, but not such a high affinity as would imply
an irreversible formation of a cyclin-kinase complex. This behavior
differs from that of classic cell cycle Cdks. For example, Desai et al.
(14) found that Cdc2 and Cdk2 activation by cyclin A and B1
corresponded to a one-to-one titration of Cdc2 or Cdk2 activity by
addition of cyclin, indicative of very high affinity and resulting in a
complex that was stable to dilution. In this regard, it is important to
recognize that Pcl10p belongs to a different family of cyclins. This
subset of yeast Pho85p cyclins, Pcl6p, Pcl7p, Pcl8p, and Pcl10p, lacks
the COOH-terminal structural repeat of the cyclin box present in cell cycle-regulated cyclins and is also characterized by
NH2-terminal extensions of unknown function and no sequence
similarity to other cyclins. It is not unreasonable, then, that this
class of cyclins differs in how it interacts with the Cdk catalytic subunit.
Our suggestion that Pho85p does not require phosphorylation at Ser166
in the activation loop for activity is in contrast to the conclusions
of Santos et al. (60) who reported that mutation of Ser166
to Ala yielded a nonfunctional Pho85p molecule as judged by its
inability to complement defects in pho85 cells. In that study, mutation to Glu resulted in a Pho85p molecule which functioned comparably to the wild type. However, others have obtained conflicting results, finding that mutation of Ser166 to Ala has no effect on the
ability of Pho85p to regulate acid phosphatase expression (22). Together with the results presented in this study, we conclude that Ser166 phosphorylation is not essential for activity. Indeed, there is a precedent for a Cdk not requiring prior
phosphorylation for activity, namely, mammalian Cdk5. This Cdk is
thought to be involved in neuronal and muscle development (36, 39,
54, 66). Cdk5 is also expressed in terminally differentiated
tissues where it is not believed to have a role in cell cycle controls. It is activated by association with p35, a protein only remotely related in sequence to cyclins (38, 56). Like Pho85p, Cdk5 can be produced in E. coli, and the addition of a truncated
form of the p35 activator also produced in E. coli can
reconstitute an active kinase complex (56). It is intriguing
that Cdk5 is the mammalian Cdk with the amino acid sequence most
similar to that of Pho85p, and we have shown that p35 can modestly
activate Pho85p (75). However, as noted above, p35 bears
almost no resemblance to Pcl10p or other Pcls, and it remains to be
established whether it functions mechanistically in a way similar to
that of Pcl10p.
In the present study, we provide evidence that Pcl10p forms complexes
with Gsy2p. First, in gel filtration studies of recombinant proteins,
the Gsy2p elution profile was markedly altered by the presence of
Pcl10p. Second, Gsy2p was present in immunoprecipitates from yeast cell
extracts using antibodies directed at an epitope tag on Pcl10p. Third,
additional evidence for the interaction came from the substrate
kinetics of the reconstituted Pho85p-Pcl10p kinase in which the level
of Pcl10p determined the Vmax with respect to
Gsy2p. This behavior is consistent with an obligate activator interacting with the substrate so that the effective substrate for the
enzyme becomes the activator-substrate complex (64), Pcl10p-Gsy2p in this case. Originally, such kinetics were observed with
enzymes that utilize ATP, where the MgATP complex is the true substrate
(see reference 40 for a comprehensive discussion). The results are also consistent with our observation that Pcl10p gave a
weak positive result with Gsy2p in a two-hybrid yeast assay (24). Synthetic peptides based on known Pho85p
phosphorylation sites were extremely poor substrates for Pho85p-Pcl10p,
with Vmax/Km ratios some
4 orders of magnitude lower than that obtained with Gsy2p. The large
difference in Vmax/Km is
due mostly to the high Km values for the peptide
substrates. We conclude not only that Pcl10p directly interacts with
Gsy2p but also that this interaction plays an important role in
substrate recognition.
Ideas about the mechanisms of protein kinase substrate specificity have
evolved significantly over the last decade or so. Initial efforts to
define recognition determinants centered on local sequence features
surrounding the modified residue (35, 52). For some kinases,
certain critical residues that define consensus sequence motifs can be
identified and short synthetic peptides of corresponding sequence serve
as effective substrates. For example, cyclic AMP-dependent protein
kinase phosphorylates the short peptide known as Kemptide virtually as
well as it does liver pyruvate kinase, the protein from which Kemptide
is derived (34). However, there are many examples of kinases
that, like Pho85p, phosphorylate short synthetic peptides poorly. Such
behavior has been attributed to a requirement for additional contacts
to be made at points removed from the site of phosphorylation in the
substrate (35) as is, we postulate, the case for
Pho85p-Pcl10p. Such contacts can be with regions of the kinase
catalytic subunit outside of the catalytic site, as in the case of JNK
phosphorylation of c-Jun (32) and Elk-1 (76).
Alternatively, a separate protein subunit may be involved (17,
51). Examples include scaffolding proteins, like Ste5p, that
allow for specific phosphorylations within the MAP kinase cascade by
sequestering protein kinases and their kinase substrates (61,
74). Another example is provided by growth factor signaling
pathways in which many Tyr phosphorylations are mediated by
noncatalytic protein-protein interactions (9, 50). A third
example is of proteins that might best be defined as targeting
subunits, akin to the multiple targeting subunits that interact with
the type 1 protein phosphatase catalytic subunit (13, 25).
Different targeting subunits direct the same catalytic subunit to
distinct functions. Such is likely to be true for Cdks in general (for
example, see references 53 and
72) and for Pho85p in particular. In fact, Pho85p
provides one of the better examples where there is evidence that
distinct targeting subunits, such as Pcl10p and Pho80p, direct the
kinase towards separate substrates both in vitro and in vivo
(24). Other recent work has suggested a targeting role also
for mammalian cyclins in retinoblastoma protein (Rb) phosphorylation. A
region of cyclin E has been identified as directing the phosphorylation
of Rb by Cdk2 (33). This region is implicated in direct
binding of cyclin E to Rb, and its removal impedes phosphorylation of
Rb by Cdk2-cyclin E but not of the generic Cdk substrate histone H1
(33). Cyclin A-mediated phosphorylation involves a
hydrophobic patch in cyclin A which is involved in targeting
Cdk2-cyclin A to specific substrates (63). Mutation of the
hydrophobic patch reduces the ability of Cdk2-cyclin A to phosphorylate Rb.
Mechanistically, targeting subunits could function in two different
ways. One mechanism would involve the formation of a complex in which
the targeting subunit contributes to the binding interaction with the
substrate during catalysis. Alternatively, the targeting subunit could
serve to increase the local concentration of substrate at the active
site of the kinase rather than to present the substrate to the kinase
in a particular orientation. In the example of Rb phosphorylation noted
above, addition of a heterologous Rb-binding sequence to the mutant
cyclin A that could not bind Rb restored Rb phosphorylation
(63). This result is consistent with increased local
concentration of substrate contributing significantly to Rb
recognition. At present, we favor a similar model for Pho85p-Pcl10p based on the enzyme kinetic data. Half-maximal activation of Pho85p by
Pcl10p occurred at ~0.2 µM whether an efficient substrate, such as
Gsy2p, or a poor substrate, such as Gsy2-654, was used. If Pcl10p
interacted simultaneously with Gsy2p and Pho85p, one would have
expected activation of Gsy2p phosphorylation to occur at lower Pcl10p
concentrations than those for peptide phosphorylation. Thus, the
results suggest that the enhanced kinetic performance with Gsy2p as a
substrate is due to a local concentration effect. However, more work is
needed to substantiate this hypothesis.
A substantial proportion of the Pho85p in yeast cell extracts exists as
a monomer, but it is also detected over a wide range of molecular
weights, as was true also for Gsy2p and Pcl10p. There was a clear
overlap of the elution of Gsy2p, Pho85p, and Pcl10p, consistent with
the proteins being present in the same complex. The Pho85p catalytic
subunit is known to interact with 10 different cyclin molecules
(16, 29, 41, 42) and the Pho81p inhibitor (48,
62), so a wide size distribution is not surprising. Additionally, if the cyclins mediate other protein-protein interactions, as we
propose for Pcl10p, even greater heterogeneity can be expected. Pcl10p
itself had an apparent molecular mass of ~110 kDa or greater which
would be consistent with formation of dimers or larger complexes. We
have yet to prove formally the presence of Pcl10p dimers, but it is
interesting that Desai et al. (14) reported that cyclins A
and B1 produced in insect cells had molecular masses of 110 and 160 kDa, respectively, as judged by gel filtration. Other relevant
protein-protein interactions include glycogen synthase binding to the
glycogenins Glg1p and Glg2p (7), the Gac1p targeting subunit
of Glc7p protein phosphatase (8), possibly other phosphatase targeting subunits (6), and glycogen particles (reviewed in reference 57). Thus, there is the potential to form
a large variety of different assemblies. From this perspective, it is not surprising that we were able to immunoprecipitate only some 20% of
the total Gsy2p from cell lysates using antibody directed to Pcl10p.
When Pcl10p was expressed from a high-copy-number plasmid, there was
sufficient overexpression to drive the majority of the Pho85p into
coelution with Pcl10p. Overexpression of Pcl10p in wild-type yeast
cells caused reduced glycogen accumulation, presumably by recruiting
more Pho85p to the control of this specific function (18).
We envisage a model for Pho85p function in which the Pcls are limiting
and Pho85p is in excess, with a significant pool of free monomer (Fig.
9). Pho85p from this free pool could be directed to specific substrates
via interactions with substrate-associated Pcls. This sequestration of
Pho85p may also involve trafficking between cellular compartments. A
large proportion of Pho85p is nuclear (30), whereas glycogen
synthesis is thought to be cytosolic. In this regard, it will be of
interest to analyze the subcellular localization of Pcl10p. As is true
for the control of the classic cell cycle Cdks, the assembly and
disassociation of Pho85p-Pcl complexes would provide mechanisms for
regulating Pho85p function. To date, little is known of this process.
In the case of the classic Cdks, the high-affinity association of the
cyclin with the Cdk necessitates regulated proteolytic degradation to
deconstruct the complex. Perhaps nonclassic cyclins like Pcl10p, which
has lower affinity for its Cdk, are subject to a different type of regulation. The mechanisms for the specific control of Pho85p function
through individual Pcls will be an important topic of future
investigation.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 9.
Model for substrate recognition by Pho85p-Pcl10p. In the
model, Pho85p is in excess of the Pcls. Free Pho85p is then recruited
to phosphorylate particular substrates via interactions between the
substrate and the appropriate Pcl. How this recruitment is regulated is
not known. Thus, in addition to activating Pho85p, the Pcls also target
the kinase to specific substrates.
|
|
 |
ACKNOWLEDGMENTS |
This work was supported in part by National Institute of Diabetes
and Digestive and Kidney Diseases grants DK27221 and DK42576 and the
Indiana University Diabetes Research and Training Center grant DK20542.
We thank Anna DePaoli-Roach, Thomas Hurley, Mark Goebl, and Ron Wek for
many helpful discussions during the course of this work and critical
comments regarding the manuscript. We thank Brenda Andrews and Dongqing
Huang for sharing reagents and results prior to publication.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biochemistry and Molecular Biology, Indiana University School of
Medicine, 635 Barnhill Dr., Indianapolis, IN 46202-5122. Phone: (317)
274-1582. Fax: (317) 274-4686. E-mail: proach{at}iupui.edu.
 |
REFERENCES |
| 1.
|
Andrews, B., and V. Measday.
1998.
The cyclin family of budding yeast: abundant use of a good idea.
Trends Genet.
14:66-72[Medline].
|
| 2.
|
Bazan, J. F.
1996.
Helical fold prediction for the cyclin box.
Proteins
24:1-17[Medline].
|
| 3.
|
Brachmann, C. B.,
A. Davies,
G. J. Cost,
E. Caputo,
J. Li,
P. Hieter, and J. D. Boeke.
1998.
Designer deletion strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications.
Yeast
14:115-132[Medline].
|
| 4.
|
Bradford, M. M.
1976.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem.
72:248-254[Medline].
|
| 5.
|
Chang, A. C. Y., and S. N. Cohen.
1978.
Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid.
J. Bacteriol.
134:1141-1156[Abstract/Free Full Text].
|
| 6.
|
Cheng, C.,
D. Q. Huang, and P. J. Roach.
1997.
Yeast PIG genes: PIG1 encodes a putative type 1 phosphatase subunit that interacts with the yeast glycogen synthase Gsy2p.
Yeast
13:1-8[Medline].
|
| 7.
|
Cheng, C.,
J. Mu,
I. Farkas,
D. Q. Huang,
M. G. Goebl, and P. J. Roach.
1995.
Requirement of the self-glucosylating initiator proteins Glg1p and Glg2p for glycogen accumulation in Saccharomyces cerevisiae.
Mol. Cell. Biol.
15:6632-6640[Abstract].
|
| 8.
| Cheng, C., and P. J. Roach. Unpublished
observations.
|
| 9.
|
Cohen, G. B.,
R. Ren, and D. Baltimore.
1995.
Modular binding domains in signal transduction proteins.
Cell
80:237-248[Medline].
|
| 10.
|
Cross, F.
1995.
Transcriptional regulation by a cyclin-cdk.
Trends Genet.
11:209-211[Medline].
|
| 11.
| Davis, M. T. 1997. Mass spectrometry methods,
ABRF '97 Tutorial 2. Presented at the 1997 Meeting of the Association
of Biomolecular Resource Facilities, Baltimore, Md., 9 February 1997.
|
| 12.
|
Davis, M. T.,
D. C. Stahl,
K. M. Swiderek, and T. D. Lee.
1994.
Capillary liquid chromatography/mass spectrometry for peptide and protein characterization.
Methods Companion Methods Enzymol.
6:304-314.
|
| 13.
|
Depaoli-Roach, A. A.,
I. K. Park,
V. Cerovsky,
C. Csortos,
S. D. Durbin,
M. J. Kuntz,
A. Sitikov,
P. M. Tang,
A. Verin, and S. Zolnierowicz.
1994.
Serine/threonine protein phosphatases in the control of cell function.
Adv. Enzyme Regul.
34:199-224[Medline].
|
| 14.
|
Desai, D.,
Y. Gu, and D. O. Morgan.
1992.
Activation of human cyclin-dependent kinases in vitro.
Mol. Biol. Cell
3:571-582[Abstract].
|
| 15.
|
Espinoza, F. H.,
A. Farrell,
H. Erdjument-Bromage,
P. Tempst, and D. O. Morgan.
1996.
A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK.
Science
273:1714-1717[Abstract/Free Full Text].
|
| 16.
|
Espinoza, F. H.,
J. Ogas,
I. Herskowitz, and D. O. Morgan.
1994.
Cell cycle control by a complex of the cyclin HCS26 (PCL1) and the kinase PHO85.
Science
266:1388-1391[Abstract/Free Full Text].
|
| 17.
|
Faux, M. C., and J. D. Scott.
1996.
Molecular glue: kinase anchoring and scaffold proteins.
Cell
85:9-12[Medline].
|
| 18.
| Fujino, M. A., and P. J. Roach.
Unpublished observations.
|
| 19.
|
Guthrie, C., and G. R. Fink (ed.).
1991.
Methods in enzymology, vol. 194. Guide to yeast genetics and molecular biology.
Academic Press, Inc., San Diego, Calif.
|
| 20.
|
Hardy, T. A.,
D. Q. Huang, and P. J. Roach.
1994.
Interactions between cAMP-dependent and SNF1 protein kinases in the control of glycogen accumulation in Saccharomyces cerevisiae.
J. Biol. Chem.
269:27907-27913[Abstract/Free Full Text].
|
| 21.
|
Hardy, T. A., and P. J. Roach.
1993.
Control of yeast glycogen synthase-2 by COOH-terminal phosphorylation.
J. Biol. Chem.
268:23799-23805[Abstract/Free Full Text].
|
| 22.
| Huang, D. Q., and B. Andrews. Personal
communication.
|
| 23.
|
Huang, D. Q.,
I. Farkas, and P. J. Roach.
1996.
Pho85p, a cyclin-dependent protein kinase, and the Snf1p protein kinase act antagonistically to control glycogen accumulation in Saccharomyces cerevisiae.
Mol. Cell. Biol.
16:4357-4365[Abstract].
|
| 24.
|
Huang, D. Q.,
J. Moffat,
W. A. Wilson,
L. Moore,
C. Cheng,
P. J. Roach, and B. Andrews.
1998.
Cyclin partners determine Pho85 protein kinase substrate specificity in vitro and in vivo: control of glycogen biosynthesis by Pcl8 and Pcl10.
Mol. Cell. Biol.
18:3289-3299[Abstract/Free Full Text].
|
| 25.
|
Hubbard, M. J., and P. Cohen.
1993.
On target with a new mechanism for the regulation of protein phosphorylation.
Trends Biochem. Sci.
18:172-177[Medline].
|
| 26.
|
Hunt, T.
1991.
Cyclins and their partners: from a simple idea to complicated reality.
Semin. Cell Biol.
2:213-222[Medline].
|
| 27.
|
Hunter, T., and G. D. Plowman.
1997.
The protein kinases of budding yeast: six score and more.
Trends Biochem. Sci.
22:18-22[Medline].
|
| 28.
|
Jeffrey, P. D.,
A. A. Ruso,
K. Polyak,
E. Gibbs,
J. Hurwitz,
J. Massague, and N. P. Pavletich.
1995.
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.
Nature
376:313-320[Medline].
|
| 29.
|
Kaffman, A.,
I. Herskowitz,
R. Tjian, and E. K. O'Shea.
1994.
Phosphorylation of the transcription factor PHO4 by a cyclin-CDK complex, PHO80-PHO85.
Science
263:1153-1156[Abstract/Free Full Text].
|
| 30.
|
Kaffman, A.,
N. M. Rank,
E. M. O'Neill,
L. S. Huang, and E. K. O'Shea.
1998.
The receptor Msn5 exports the phosphorylated transcription factor Pho4 out of the nucleus.
Nature
396:482-486[Medline].
|
| 31.
|
Kaldis, P.,
A. Sutton, and M. J. Solomon.
1996.
The Cdk-activating kinase (CAK) from budding yeast.
Cell
86:553-564[Medline].
|
| 32.
|
Kallunki, T.,
B. Su,
I. Tsigelny,
H. K. Sluss,
B. Derijard,
G. Moore,
R. Davis, and M. Karin.
1994.
JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation.
Genes Dev.
8:2996-3007[Abstract/Free Full Text].
|
| 33.
|
Kelly, B. L.,
K. G. Wolfe, and J. M. Roberts.
1998.
Identification of a substrate-targeting domain in cyclin E necessary for phosphorylation of the retinoblastoma protein.
Proc. Natl. Acad. Sci. USA
95:2535-2540[Abstract/Free Full Text].
|
| 34.
|
Kemp, B. E.,
D. J. Graves,
E. Benjamini, and E. G. Krebs.
1977.
Role of multiple basic residues in determining the substrate specificity of cyclic AMP-dependent protein kinase.
J. Biol. Chem.
252:4888-4894[Free Full Text].
|
| 35.
|
Kemp, B. E., and R. B. Pearson.
1991.
Design and use of peptide substrates for protein kinases.
Methods Enzymol.
200:121-134[Medline].
|
| 36.
|
Lazaro, J. B.,
M. Kitzmann,
M. A. Poul,
M. Vandromme,
N. J. Lamb, and A. Fernandez.
1997.
Cyclin dependent kinase 5, cdk5, is a positive regulator of myogenesis in mouse C2 cells.
J. Cell Sci.
110:1251-1260[Abstract].
|
| 37.
|
Lenburg, M. E., and E. K. Oshea.
1996.
Signaling phosphate starvation.
Trends Biochem. Sci.
21:383-387[Medline].
|
| 38.
|
Lew, J.,
Q. Q. Huang,
Z. Qi,
R. J. Winkfein,
R. Aebersold,
T. Hunt, and J. H. Wang.
1994.
A brain-specific activator of cyclin-dependent kinase 5.
Nature
371:423-426[Medline].
|
| 39.
|
Lew, J., and J. H. Wang.
1995.
Neuronal cdc2-like kinase.
Trends Biochem. Sci.
20:33-37[Medline].
|
| 40.
|
London, W. P., and T. L. Steck.
1969.
Kinetics of enzyme reactions with interaction between a substrate and a (metal) modifier.
Biochemistry
8:1767-1779[Medline].
|
| 41.
|
Measday, V.,
L. Moore,
J. Ogas,
M. Tyers, and B. Andrews.
1994.
The PCL2 (ORFD)-PHO85 cyclin-dependent kinase complex: a cell cycle regulator in yeast.
Science
266:1391-1395[Abstract/Free Full Text].
|
| 42.
|
Measday, V.,
L. Moore,
R. Retnakaran,
J. Lee,
M. Donoviel,
A. M. Neiman, and B. Andrews.
1997.
A family of cyclin-like proteins that interact with the Pho85 cyclin-dependent kinase.
Mol. Cell. Biol.
17:1212-1223[Abstract].
|
| 43.
|
Morgan, D. O.
1997.
Cyclin-dependent kinases: engines, clocks, and microprocessors.
Annu. Rev. Cell Dev. Biol.
13:261-291[Medline].
|
| 44.
|
Morgan, D. O.
1995.
Principles of CDK regulation.
Nature
374:131-134[Medline].
|
| 45.
|
Morgan, D. O.,
R. P. Fisher,
F. H. Espinoza,
A. Farrell,
J. Nourse,
H. Chamberlin, and P. Jin.
1998.
Control of eukaryotic cell cycle progression by phosphorylation of cyclin-dependent kinases.
Cancer J. Sci. Am.
4:S77-S83.
|
| 46.
|
Nigg, E. A.
1996.
Cyclin-dependent kinase 7: at the cross-roads of transcription, DNA repair and cell cycle control?
Curr. Opin. Cell Biol.
8:312-317[Medline].
|
| 47.
|
O'Neill, E. M.,
A. Kaffman,
E. R. Jolly, and E. K. O'Shea.
1996.
Regulation of PHO4 nuclear localization by the PHO80-PHO85 cyclin-CDK complex.
Science
271:209-212[Abstract].
|
| 48.
|
Ogawa, N.,
K.-I. Noguchi,
H. Sawai,
Y. Yamashita,
C. Yompakdee, and Y. Oshima.
1995.
Functional domains of Pho81p, an inhibitor of Pho85p protein kinase, in the transduction pathway of Pi signals in Saccharomyces cerevisiae.
Mol. Cell. Biol.
15:997-1004[Abstract].
|
| 49.
|
Olson, M. V.,
J. E. Dutchik,
M. Y. Graham,
G. M. Brodeur,
C. Helms,
M. Frank,
M. MacCollin,
R. Scheinman, and T. Frank.
1986.
Random-clone strategy for genomic restriction mapping in yeast.
Proc. Natl. Acad. Sci. USA
83:7826-7830[Abstract/Free Full Text].
|
| 50.
|
Pawson, T.
1995.
Protein modules and signalling networks.
Nature
373:573-580[Medline].
|
| 51.
|
Pawson, T., and J. D. Scott.
1997.
Signaling through scaffold, anchoring, and adaptor proteins.
Science
278:2075-2080[Abstract/Free Full Text].
|
| 52.
|
Pearson, R. B.,
K. I. Mitchelhill, and B. E. Kemp.
1993.
Studies of protein kinase/phosphatase specificity using synthetic peptides, p. 265-291.
In
D. G. Hardie (ed.), Protein phosphorylation: a practical approach. IRL Press, Oxford, United Kingdom.
|
| 53.
|
Peeper, D. S.,
L. L. Parker,
M. E. Ewen,
M. Toebes,
F. L. Hall,
M. Xu,
A. Zantema,
A. J. van der Eb, and H. Piwnica-Worms.
1993.
A- and B-type cyclins differentially modulate substrate specificity of cyclin-cdk complexes.
EMBO J.
12:1947-1954[Medline].
|
| 54.
|
Philpott, A.,
E. B. Porro,
M. W. Kirschner, and L. H. Tsai.
1997.
The role of cyclin-dependent kinase 5 and a novel regulatory subunit in regulating muscle differentiation and patterning.
Genes Dev.
11:1409-1421[Abstract/Free Full Text].
|
| 55.
|
Poon, R. Y., and T. Hunter.
1995.
Cell regulation. Innocent bystanders or chosen collaborators?
Curr. Biol.
5:1243-1247[Medline].
|
| 56.
|
Qi, Z.,
Q. Q. Huang,
K. Y. Lee,
J. Lew, and J. H. Wang.
1995.
Reconstitution of neuronal Cdc2-like kinase from bacteria-expressed Cdk5 and an active fragment of the brain-specific activator. Kinase activation in the absence of Cdk5 phosphorylation.
J. Biol. Chem.
270:10847-10854[Abstract/Free Full Text].
|
| 57.
|
Roach, P. J.,
C. Cheng,
D. Huang,
A. Lin,
J. Mu,
A. V. Skurat,
W. A. Wilson, and L. Zhai.
1999.
Novel aspects of the regulation of glycogen storage.
J. Basic Clin. Physiol. Pharmacol.
9:139-151.
|
| 58.
|
Rothman-Denes, L. B., and E. Cabib.
1970.
Two forms of yeast glycogen synthetase and their role in glycogen accumulation.
Proc. Natl. Acad. Sci. USA
66:967-974[Abstract/Free Full Text].
|
| 59.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 60.
|
Santos, R. C.,
N. C. Waters,
C. L. Creasy, and L. W. Bergman.
1995.
Structure-function relationships of the yeast cyclin-dependent kinase Pho85.
Mol. Cell. Biol.
15:5482-5491[Abstract].
|
| 61.
|
Schaeffer, H. J., and M. J. Weber.
1999.
Mitogen-activated protein kinases: specific messages from ubiquitous messengers.
Mol. Cell. Biol.
19:2435-2444[Free Full Text].
|
| 62.
|
Schneider, K. R.,
R. L. Smith, and E. K. O'Shea.
1994.
Phosphate-regulated inactivation of the kinase PHO80-PHO85 by the CDK inhibitor PHO81.
Science
266:122-126[Abstract/Free Full Text].
|
| 63.
|
Schulman, B. A.,
D. L. Lindstrom, and E. Harlow.
1998.
Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A.
Proc. Natl. Acad. Sci. USA
95:10453-10458[Abstract/Free Full Text].
|
| 64.
|
Segel, I. H.
1975.
Enzyme kinetics, p. 242-250.
John Wiley and Sons, New York, N.Y.
|
| 65.
|
Sikorski, R. S., and P. Hieter.
1989.
A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae.
Genetics
122:19-27[Abstract/Free Full Text].
|
| 66.
|
Tang, D.,
K. Y. Lee,
Z. Qi,
I. Matsuura, and J. H. Wang.
1996.
Neuronal Cdc2-like kinase: from cell cycle to neuronal function.
Biochem. Cell Biol.
74:419-429[Medline].
|
| 67.
|
Tennyson, C. N.,
J. Lee, and B. J. Andrews.
1998.
A role for the Pcl9-Pho85 cyclin-cdk complex at the M/G(1) boundary in Saccharomyces cerevisiae.
Mol. Microbiol.
28:69-79[Medline].
|
| 68.
|
Thomas, J. A.,
K. K. Schlender, and J. Larner.
1968.
A rapid filter paper assay for UDPglucose-glycogen glucosylltransferase, including an improved biosynthesis of UDP-14C-glucose.
Anal. Biochem.
25:486-499[Medline].
|
| 69.
|
Thuret, J. Y.,
J. G. Valay,
G. Faye, and C. Mann.
1996.
Civ1 (CAK in vivo), a novel Cdk-activating kinase.
Cell
86:565-576[Medline].
|
| 70.
|
Timblin, B. K.,
K. Tatchell, and L. W. Bergman.
1996.
Deletion of the gene encoding the cyclin-dependent protein kinase Pho85 alters glycogen metabolism in Saccharomyces cerevisiae.
Genetics
143:57-66[Abstract].
|
| 71.
|
Toh-e, A.,
K. Tanaka,
Y. Uesono, and R. B. Wickner.
1988.
PHO85, a negative regulator of the PHO system, is a homolog of the protein kinase gene, CDC28, of Saccharomyces cerevisiae.
Mol. Gen. Genet.
214:162-164[Medline].
|
| 72.
|
Tyers, M.,
G. Tokiwa, and B. Futcher.
1993.
Comparison of the Saccharomyces cerevisiae G1 cyclins: Cln3 may be an upstream activator of Cln1, Cln2 and other cyclins.
EMBO J.
12:1955-1968[Medline].
|
| 73.
|
Uesono, Y.,
M. Tokai,
K. Tanaka, and A. Tohe.
1992.
Negative regulators of the PHO system of Saccharomyces cerevisiae: characterization of PHO80 and PHO85.
Mol. Gen. Genet.
231:426-432[Medline].
|
| 74.
|
Whitmarsh, A. J., and R. J. Davis.
1998.
Structural organization of MAP-kinase signaling modules by scaffold proteins in yeast and mammals.
Trends Biochem. Sci.
23:481-485[Medline].
|
| 75.
| Wilson, W. A., A. Lin, and P. J. Roach.
Unpublished observations.
|
| 76.
|
Yang, S.-H.,
A. J. Whitmarsh,
R. J. Davis, and A. D. Sharrocks.
1998.
Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1.
EMBO J.
17:1740-1749[Medline].
|
Molecular and Cellular Biology, October 1999, p. 7020-7030, Vol. 19, No. 10
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Streckfuss-Bomeke, K., Schulze, F., Herzog, B., Scholz, E., Braus, G. H.
(2009). Degradation of Saccharomyces cerevisiae Transcription Factor Gcn4 Requires a C-Terminal Nuclear Localization Signal in the Cyclin Pcl5. Eukaryot Cell
8: 496-510
[Abstract]
[Full Text]
-
Aviram, S., Simon, E., Gildor, T., Glaser, F., Kornitzer, D.
(2008). Autophosphorylation-Induced Degradation of the Pho85 Cyclin Pcl5 Is Essential for Response to Amino Acid Limitation. Mol. Cell. Biol.
28: 6858-6869
[Abstract]
[Full Text]
-
Bomeke, K., Pries, R., Korte, V., Scholz, E., Herzog, B., Schulze, F., Braus, G. H.
(2006). Yeast Gcn4p Stabilization Is Initiated by the Dissociation of the Nuclear Pho85p/Pcl5p Complex. Mol. Biol. Cell
17: 2952-2962
[Abstract]
[Full Text]
-
Wilson, W. A., Skurat, A. V., Probst, B., de Paoli-Roach, A., Roach, P. J., Rutter, J.
(2005). Control of mammalian glycogen synthase by PAS kinase. Proc. Natl. Acad. Sci. USA
102: 16596-16601
[Abstract]
[Full Text]
-
Gildor, T., Shemer, R., Atir-Lande, A., Kornitzer, D.
(2005). Coevolution of Cyclin Pcl5 and Its Substrate Gcn4. Eukaryot Cell
4: 310-318
[Abstract]
[Full Text]
-
Bouchoux, C., Hautbergue, G., Grenetier, S., Carles, C., Riva, M., Goguel, V.
(2004). CTD kinase I is involved in RNA polymerase I transcription. Nucleic Acids Res
32: 5851-5860
[Abstract]
[Full Text]
-
Keniry, M. E., Kemp, H. A., Rivers, D. M., Sprague, G. F. Jr.
(2004). The Identification of Pcl1-Interacting Proteins That Genetically Interact With Cla4 May Indicate a Link Between G1 Progression and Mitotic Exit. Genetics
166: 1177-1186
[Abstract]
[Full Text]
-
Wiatrowski, H. A., van Denderen, B. J. W., Berkey, C. D., Kemp, B. E., Stapleton, D., Carlson, M.
(2004). Mutations in the Gal83 Glycogen-Binding Domain Activate the Snf1/Gal83 Kinase Pathway by a Glycogen-Independent Mechanism. Mol. Cell. Biol.
24: 352-361
[Abstract]
[Full Text]
-
Shemer, R., Meimoun, A., Holtzman, T., Kornitzer, D.
(2002). Regulation of the Transcription Factor Gcn4 by Pho85 Cyclin Pcl5. Mol. Cell. Biol.
22: 5395-5404
[Abstract]
[Full Text]
-
Huang, D., Moffat, J., Andrews, B.
(2002). Dissection of a Complex Phenotype by Functional Genomics Reveals Roles for the Yeast Cyclin-Dependent Protein Kinase Pho85 in Stress Adaptation and Cell Integrity. Mol. Cell. Biol.
22: 5076-5088
[Abstract]
[Full Text]
-
Anderson, C., Tatchell, K.
(2001). Hyperactive Glycogen Synthase Mutants of Saccharomyces cerevisiae Suppress the glc7-1 Protein Phosphatase Mutant. J. Bacteriol.
183: 821-829
[Abstract]
[Full Text]
-
Lenburg, M. E., O'Shea, E. K.
(2001). Genetic Evidence for a Morphogenetic Function of the Saccharomyces cerevisiae Pho85 Cyclin-Dependent Kinase. Genetics
157: 39-51
[Abstract]
[Full Text]
-
Enjalbert, B., Parrou, J. L., Vincent, O., François, J.
(2000). Mitochondrial respiratory mutants of Saccharomyces cerevisiae accumulate glycogen and readily mobilize it in a glucose-depleted medium. Microbiology
146: 2685-2694
[Abstract]
[Full Text]
-
Meimoun, A., Holtzman, T., Weissman, Z., McBride, H. J., Stillman, D. J., Fink, G. R., Kornitzer, D.
(2000). Degradation of the Transcription Factor Gcn4 Requires the Kinase Pho85 and the SCFCDC4 Ubiquitin-Ligase Complex. Mol. Biol. Cell
11: 915-927
[Abstract]
[Full Text]
-
Pederson, B. A., Cheng, C., Wilson, W. A., Roach, P. J.
(2000). Regulation of Glycogen Synthase. IDENTIFICATION OF RESIDUES INVOLVED IN REGULATION BY THE ALLOSTERIC LIGAND GLUCOSE-6-P AND BY PHOSPHORYLATION. J. Biol. Chem.
275: 27753-27761
[Abstract]
[Full Text]